Drugs / Anti-CD30 CAR T cells
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06756321 | Sep 2023 → Mar 2025 overdue | leukemia, lymphoma | Affiliated Hospital of Nantong University | Recruiting | No outcome recorded |
| Phase 0 | NCT05208853 | Feb 2022 | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, Hodgkins lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma +2 | Zhejiang University | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04008394 | Jul 2019 → Jul 2022 | Hodgkins lymphoma, adult T-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02274584 | Mar 2014 → Oct 2016 | lymphoma | Peking University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti CD30 CAR T Cells | “Anti CD30 CAR T Cells” NCT05208853 ↗ |
| Action | Deplete | “effective killing of CD30 target cells” NCT02274584 ↗ |
| Modality | Cell therapy | “CAR-modified T cells” NCT02274584 ↗ |
| Route | Intravenous | “Route of administration: Intravenous injection.” NCT05208853 ↗ |